Medline secondary offering

Medline files to sell 60 million shares in secondary offering

Selling stockholders will offer the Class A shares, and Medline agreed to repurchase $200 million of stock from them at the offering price. The company gets no proceeds.

By Elliot Marsh, Startups and markets correspondent2 min read
Illustration: Medline headquarters Northfield Illinois
Illustration: Medline headquarters Northfield Illinois Illustration: Venturist

Medline Inc. filed a preliminary prospectus with the SEC on November 16 for an offering of 60 million shares of Class A common stock by selling stockholders, according to the filing. Medline will receive none of the proceeds from the share sale. The registration statement has not yet become effective, and the shares cannot be sold until it does.

The company and Medline Holdings agreed to repurchase $200 million of shares and common units directly from the selling stockholders at the price paid by underwriters in the offering, the filing says. At the assumed price of $39.47, the Nasdaq closing price on November 13, that would represent about 5.07 million shares and units. The filing says the repurchase should close at the same time as the offering, though the offering can proceed without it.

Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan are listed as global coordinators and joint bookrunning managers. Blackstone Capital Markets and Carlyle are co-managers. The underwriters have a 30-day option to buy up to 9 million additional shares from the selling stockholders.

Prior to the offering, certain selling stockholders will exchange common units of Medline Holdings for shares of Class A common stock to be sold in the offering, the filing says. According to the filing, Medline Inc. is a holding company whose only material assets are its direct and indirect equity interests in Medline Holdings.

Medline went public in December 2025, and its Class A stock trades on Nasdaq under MDLN. The prospectus calls Medline the biggest supplier of medical-surgical products and supply chain services, offering roughly 335,000 items. It operates two segments: Medline Brand, with about 190,000 products, and Supply Chain Solutions, with about 145,000 third-party products.

The filing shows that for 2025, Medline's net sales reached $28.4 billion, net income was $1.2 billion, and adjusted EBITDA came to $3.5 billion. During the first nine months of 2026, net sales totaled $22.9 billion, net income was $0.7 billion, and adjusted EBITDA was $2.8 billion.

The filing also says Medline has 30 manufacturing facilities, 70 distribution centers, and more than 45,000 employees, with next-day delivery to 95% of U.S. customers. Its Prime Vendor retention rate has averaged above 98% over the past five years.

The filing states that net sales have grown every year since the company was founded, with a compound annual growth rate of 18% since inception and roughly 13% over the past decade. Nearly 90% of that growth was organic, and about 90% of Medline Brand net sales were recurring for 2025, according to the prospectus.

Sources: Medline Inc. (SEC filing)

To report an error in this article, write to corrections@venturistnews.com. Corrections log.

Elliot Marsh covers startups, IPO filings and the money behind them for Venturist. Elliot writes from SEC filings, company announcements and published reporting.

More from Elliot